Stevens Capital Management LP Purchases Shares of 5,801 bluebird bio Inc (BLUE)

Stevens Capital Management LP purchased a new stake in shares of bluebird bio Inc (NASDAQ:BLUE) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 5,801 shares of the biotechnology company’s stock, valued at approximately $847,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. FMR LLC boosted its position in shares of bluebird bio by 8.1% during the 3rd quarter. FMR LLC now owns 8,123,687 shares of the biotechnology company’s stock worth $1,186,058,000 after purchasing an additional 605,797 shares in the last quarter. BlackRock Inc. boosted its position in shares of bluebird bio by 7.9% during the 3rd quarter. BlackRock Inc. now owns 2,952,089 shares of the biotechnology company’s stock worth $431,005,000 after purchasing an additional 216,914 shares in the last quarter. OppenheimerFunds Inc. boosted its position in shares of bluebird bio by 3.0% during the 2nd quarter. OppenheimerFunds Inc. now owns 794,126 shares of the biotechnology company’s stock worth $124,638,000 after purchasing an additional 23,016 shares in the last quarter. First Trust Advisors LP boosted its position in shares of bluebird bio by 63.2% during the 3rd quarter. First Trust Advisors LP now owns 601,883 shares of the biotechnology company’s stock worth $87,875,000 after purchasing an additional 233,175 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of bluebird bio by 86.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 581,695 shares of the biotechnology company’s stock worth $84,926,000 after purchasing an additional 269,074 shares in the last quarter.

BLUE opened at $102.23 on Friday. bluebird bio Inc has a fifty-two week low of $100.99 and a fifty-two week high of $236.17. The stock has a market capitalization of $5.95 billion, a P/E ratio of -13.26 and a beta of 2.37.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.90) by $0.17. The firm had revenue of $11.50 million during the quarter, compared to analyst estimates of $6.90 million. bluebird bio had a negative net margin of 1,326.02% and a negative return on equity of 31.50%. The company’s revenue for the quarter was up 49.2% on a year-over-year basis. During the same quarter last year, the business posted ($1.73) EPS. Analysts expect that bluebird bio Inc will post -10.71 earnings per share for the current fiscal year.

A number of research firms have recently issued reports on BLUE. William Blair reissued a “buy” rating on shares of bluebird bio in a research report on Wednesday, September 5th. Cantor Fitzgerald set a $122.00 price objective on shares of bluebird bio and gave the stock a “sell” rating in a research report on Wednesday, September 5th. BidaskClub cut shares of bluebird bio from a “hold” rating to a “sell” rating in a research report on Tuesday, September 11th. ValuEngine raised shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 2nd. Finally, Goldman Sachs Group cut shares of bluebird bio from a “conviction-buy” rating to a “buy” rating in a research report on Friday, September 21st. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and seventeen have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $194.80.

In other bluebird bio news, COO Susanna Gatti High sold 1,890 shares of the stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $113.83, for a total value of $215,138.70. Following the completion of the sale, the chief operating officer now owns 15,610 shares in the company, valued at approximately $1,776,886.30. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider David Davidson sold 5,000 shares of the stock in a transaction dated Tuesday, October 2nd. The shares were sold at an average price of $139.32, for a total transaction of $696,600.00. Following the completion of the sale, the insider now owns 29,905 shares of the company’s stock, valued at approximately $4,166,364.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,490 shares of company stock valued at $2,901,186. Company insiders own 3.00% of the company’s stock.

WARNING: This report was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2018/12/08/stevens-capital-management-lp-purchases-shares-of-5801-bluebird-bio-inc-blue.html.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

See Also: Book Value Per Share in Stock Trading

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply